A Declaration from Members of the World's Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders – healthcare providers, governments, multilateral organizations, and non-governmental donor organizations – to ensure that COVID vaccines and treatments get to the patients in the world who most need them. We are working hard to fulfill this responsibility.

- Our sector must continue to play a constructive, proactive part in developing COVID solutions and the global manufacturing capacity to produce them. In the past year, over 950 global R&D projects have been launched on COVID vaccines, treatments, and biologics, as companies have diverted efforts from other projectsⁱ. 70 percent of these projects are by small and medium sized companiesⁱⁱ. Over 250 global partnerships have been formed to build manufacturing capacityⁱⁱⁱ. And we are working hard to do more.
- Intellectual property is the foundation of our sector. It is responsible for creating the global biotech network that responded so quickly to the COVID crisis in the first place. It is what gives investors the confidence to fund companies with long time horizons and high risks. It gave companies the assurance that they could quickly pivot during the early days of the pandemic into COVID projects. And it helped ensure the type of global cooperation and partnerships that are driving companies, countries, and manufacturers to quickly scale up the production.
- We support strong, collaborative efforts like those endorsed by the G-20^{iv} to address the global imbalances in access to COVID vaccines and treatments. Success will require national governments to address legislative or contractual impediments to supplying populations in need, especially in low- and middle- income countries. Bottlenecks and shortages in global supply chains for vaccine production need to be urgently addressed. And strained health-care systems in low-andmiddle-income countries need significant support to ensure vaccines get to people.
- The proposed "waiver" of intellectual property rights proposed in the World Trade Organization (WTO) will be ineffective and counterproductive in addressing this crisis. Intellectual property rights are *not* responsible for the imbalance in COVID vaccine supplies between higher and lower income countries. It will create a long contentious global negotiation that will not urgently address the crisis, and foster more "vaccine nationalism," exacerbating shortages in an already strained global supply chain. It would divert limited resources from companies that are focused on maximizing current global partnerships while maintaining quality and patient safety. Lastly, it would send a powerful signal to the biotech sector and investors to avoid taking the risks to develop solutions in future public health emergencies.
- Current estimates are that existing global vaccine manufacturers will produce more than 11 billion doses of COVID vaccines in 2021^v, and significantly more in the first part of 2022. We are committed to working with other global stakeholders to see that these doses get to those that most need them, wherever they may be.

Company Signatories

United States of America

Alabama

Kanti Sunkavalli, CEO, Agile Biodetection Karim Budhwani, CEO, CerFlux, Inc. Deborah Bidanset, COO, SunFire Biotechnologies LLC John Bowman, CEO, Sure Med Compliance

California

Sam Alworth, CEO, AcuraStem Marilyn Bruno, CEO, Aequor, Inc. Robert Bradway, CEO, Amgen Gail Maderis, President & CEO, Antiva Biosciences, Inc. Frank Watanabe, President & CEO, Arcutis Biotherapeutics Michael Raab, President & CEO, Ardelyx James Mackay, President & CEO, Aristea Therapeutics Jeffrey Cleland, CEO, Ashvattha Therapeutics, Inc Wilson Xu, CEO, Balto Pharmaceuticals, Inc. Niquette Hunt, CEO, Candesant Biomedical Rachel Haurwitz, President & CEO, Caribou Biosciences, Inc. Michael Narachi, President & CEO, CODA Biotherapeutics John Nicols, President & CEO, Codexis, Inc Sujal Shah, CEO, CymaBay Therapeutics Ryan Beal, CEO, Dyve Biosciences Luis Pena, President & CEO, Evommune, Inc. Michael Morrissey, President & CEO, Exelixis Alexander Hardy, CEO, Genentech Ted Love, CEO, Global Blood Therapeutics Francisco LePort, CEO, Gordian Biotechnology Robert Bernard, CEO, Ichor Medical Systems, Ins Grace Colon, CEO & President, InCarda Therapeutics Brett Monia, CEO, Ionis Frederick G. Vogt, Interim CEO, President & General Counsel, Iovance Biotherapeutics Michael Miille, CEO, Joyn Bio Rohit Shukla, CEO, Larta Guy Iannuzzi, CEO, Mentus Howard Robin, CEO, Nektar Therapeutics Paul Hastings, President & CEO, Nkarta Therapeutics Francis Parnell, Chairman & CEO, Parnell Pharmaceuticals, Inc. Jennifer Cheng, President & CEO, PTM Therapeutics, Inc. Paul Mola, President & CEO, Roswell Biotechnologies Inc. Rosemarie Christopher, President, RxRS CRO Brian Neman, CEO, Sanguine BioSciences, INC. Larry Stambaugh, Chairman & CEO, Sarmal, Inc. Craig Parker, CEO, Surrozen, Inc William Newell, CEO, Sutro Biopharma, Inc. David Webb, CEO, Synbal, Inc. Oliver Fetzer, CEO, Synthetic Genomics Sen Sundaram, CEO, Terns Pharmaceuticals, Inc.

Rick Winningham, CEO, Theravance BioPharma Eric Dube, President & CEO, Travere Therapeutics Bonnie Anderson, Executive Chairwoman, Veracyte, Inc. George Scangos, CEO, Vir Biotechnology Keith Murphy, CEO, Viscient Biosciences

Colorado

Ron Lowy, Executive Chairman, PharmaJet

Connecticut Jeff Kindler, CEO, Centrexion Therapeutics Erika Smith, CEO, ReNetX Bio

Delaware Hervé Hoppenot, CEO, Incyte

Florida

Susan Washer, President & CEO, AGTC John Crowley, Chairman & CEO, Amicus Therapeutics Marc Thibonnnier, Founder & President, AptamiR Therapeutics, Inc. James Sapirstein, President & CEO, Azurrx Biopharma

Georgia

Ajay Houde, Co-Founder & CEO, Annoviant, LLC (F/K/A TGen Tech, LLC) Steven Damon, CEO, Micron Biomedical

Illinois

Richard Gonzalez, Chairman of the Board & CEO, AbbVie

Indiana

David Ricks, Chairman & CEO, Eli Lilly and Company

Massachusetts

Habib Dable, President & CEO, Acceleron Pharma Jackie Fouse, CEO, Agios Pharmaceuticals John Butler, President & CEO, Akebia Therapeutics Ludwig Hantson, CEO, Alexion Pharmaceuticals, Inc. Richard Pops, Chairman & CEO, Alkermes John Maraganore, CEO, Alnylam Pharmaceuticals Sylvia Wulf, President & CEO, AquaBounty Technologies, Inc. Tim Van Hauwermeiren, CEO & Co-Founder, argenx Alicia Secor, CEO, Atalanta Therapeutics John Oyler, Co-Founder, Chairman, & CEO, BeiGene Michel Vounatsos, CEO, Biogen Inc. Nick Leschly, CEO, bluebird bio Melissa Bradford-Klug, President, Citrine Medicine Ranjeet Banerjee, CEO, Cold Chain Technologies Laurence Reid, CEO, Decibel Therapeutics David Lucchino, CEO, Frequency Therapeutics Chip Clark, President & CEO, Genocea Biosciences, Inc. Jeff Livingstone, CEO, Igia Pharmaceuticals

Mark Enyedy, President & CEO, ImmunoGen Adelene Perkins, CEO & Chair, Infinity Pharmaceuticals Richard Paulson, President & CEO, Karyopharm Louis Arcudi, CEO, Millendo Stephane Bancel, CEO, Moderna Gary S. Gillheeney, Sr., President & CEO, Organogenesis Stephen Yoder, President & CEO, Pieris Pharmaceuticals Pablo Cagnoni, CEO, Rubius Therapeutics Rogerio Vivaldi, President & CEO, Sigilon Therapeutics Tony Loebel, President & CEO, Sunovion Nancy Simonian, CEO, Syros Pharmaceuticals Marc Casper, Chairman, President & CEO, Thermo Fisher Scientific Inc. David Hoey, CEO, Vaxxas Inc. Jeff Baxter, President & CEO, VBI Vaccines Reshma Kewalramani, CEO & President, Vertex Pharmaceuticals Inc. Paula Ragan, CEO, X4 Pharmaceuticals Inc. Chris Garabedian, Chairman & CEO, Xontogeny

Maryland

Robert G. Kramer, President & CEO, Emergent BioSolutions Rachel King, CEO, GlycoMimetics, Inc. Scott Koenig, President & CEO, MacroGenics, Inc. Stanley Erck, President & CEO, Novavax, Inc. Oliver Schacht, President & CEO, OpGen Inc. Ken Mills, President & CEO, REGENXBIO Inc.

Michigan Mina Sooch, CEO, Ocuphire Pharma

Minnesota

Mark Platt, President & CEO, Recombinetics, Inc. Arkadiusz Dudek, CEO, TTC Oncology

North Carolina

Arthur Alfaro, CEO & Director, 21MedTech John Temperato, President & CEO, 9 Meters Biopharma Jerzy Szewczyk, CEO, BioKier Inc. Damian Shea, President, Statera Environmental Inc. Anna Rath, CEO, Vestaron Jian Bao, Co-Founder & CEO, ZY Therapeutics Inc. Jason Zhou, CEO, Zymeron Corporation

New Jersey

Giovanni Caforio, CEO, Bristol Myers Squibb Ivan Cheung, Chairman, Eisai Inc. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson Mark Trudeau, President & CEO, Mallinckrodt Pharmaceuticals Kenneth C. Frazier, CEO, Merck Alex Martin, CEO, Palladio Biosciences Stuart Peltz, CEO, PTC Therapeutics *New Mexico* Robert Curtis, President & CEO, Respira Therapeutics, Inc.

New York

Ron Cohen, President & CEO, Acorda Therapeutics, Inc. Chandrabali Ghose-Paul, CEO, Bioharmony Therapeutics Jeremy Levin, CEO, Ovid Therapeutics Albert Bourla, CEO, Pfizer Phil Gomez, CEO, SIGA Technologies, Inc. Kaspar Baenziger, CEO, Spicona Rashida Karmali, CEO, Tactical Therapeutics Inc.

Oklahoma

Colin Cumming, CEO, SensiQ

Pennsylvania

Wei He, Inventor, Founder & CEO, DTRM Biopharma Briggs Morrison, CEO, Syndax Carrie Bourdow, President & CEO, Trevena, Inc. Albert Gianchetti, President & CEO, XyloCor Therapeutics

South Carolina

Richard Alberti, Chief Operating Officer, Medpoint Lou Kennedy, CEO, Nephron Pharmaceuticals David Stefanich, CEO, RYMEDI inc. Shawn Regan, CEO, Rhythmlink International, LLC Cephus Simmons, Founder/CEO, SealCath, LLC Bruce Johnson, CEO, Stomagienics, Inc. Shea Harrelson, Co-Founder, Vikor Scientific John Carrington, CEO, ZVerse Scott Pancoast, CEO & Founder, Zylö Therapeutics Inc.

South Dakota

Eddie Sullivan, President & CEO, SAB Biotherapeutics, Inc.

Texas Linnea Fletcher, Executive Director, InnovATEBIO

Utah

Myles Greenberg, President & CEO, Alucent Biomedical Inc. Rob Etherington, CEO, Clene, Inc. Flagg Flanagan, CEO & Chairman of the Board, DiscGenics, Inc.

Virginia David Kalergis, CEO, Atelerix Life Sciences Inc.

Washington Bradford Zakes, President & CEO, Cerevast Medical, Inc. Eric Dobmeier, President & CEO, Chinook Therapeutics Steve Harr, CEO, Sana Biotechnologies Wisconsin David Kettner, President, Virent

United Kingdom

Iraj Ali, CEO, Achilles Therapeutics Claire Thompson, CEO, Agility Life Sciences David Miles, CEO, AKL Research and Development Richard Waterfield, CEO, AngioDesign Ross Breckenridge, CEO, Arjuna Therapeutics David Reynolds, CEO, AstronauTx Kevin Lee, CEO, Bicycle Therapeutics Erik Miljan, CEO, BioDivide Limited Alison Clayton, CEO, Biogelx Stefan Ogrodzinski, CEO, BioStatus Group Matthew Durdy, CEO, Cell and Gene Therapy Catapult Will West, CEO, CellCentric Euan Cameron, CEO, Cohesion Medical Ltd Carolyn Porter, CEO, CytoSeek Mark Warne, CEO, DeepMatter Group Martin Whitaker, CEO, Diurnal Group Anthony Finbow, CEO, Eagle Genomics David Hipkiss, CEO, Enesi Pharma Limited Tim Wilson, CEO, Epsilogen Ltd Werner Lanthaler, CEO, Evotec Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies Bernard Gilly, CEO, GenSight Biologics Peter Jackson, CEO, INFEX Therapeutics Ian Fotheringham, CEO, Ingenza Wayne Channon, CEO, iosBio Simon Saxby, CEO, Leaf Expression Systems David Reynolds, CEO, LoQus23 Therapeutics Ian Abercrombie, CEO, Medannex Barry Sharples, CEO, Micregen Darrin M Disley, CEO, Mogrify Deborah ONeil, CEO, NovaBiotics Rosamond Deegan, CEO, OMass Therapeutics Henrik Hagemann, CEO, Puraffinity Lisa Anson, CEO, Redx Pharma Pieter-Willem Histsma Mulier, CEO, RevoluGen Cliff Holloway, CEO, Scancell Holdings Greg Madison, CEO, Shield Therapeutics Malcolm Weir, CEO, Sosei Heptares Charlotte Casebourne, CEO, Theolytics Jonny Ohlson, CEO, Touchlight Genetics Ltd Malcolm Boyce, CEO, Trio Medicines Limited Bill Enright, CEO, Vaccitech Ltd Suzanne Dilly, CEO, ValiRx

Netherlands

Michiel Lodder, CEO, 20Med Therapeutics Pieter Gaillard, CEO, 2-BBB Medicines BV Bas Reichert, CEO, BaseClear BV Herman Steen, CEO, BiOrion Technologies BV Bertus Quint, CEO & Founder, DEBx Medical BV Jos Lunenberg, CEO, ENPICOM BV Onno van de Stolpe, CEO, Galapagos Jan van de Winkel, CEO, Genmab A/S Roel Schaapveld, CEO, InteRNA Technologies B.V. Remko van Leeuwen, CEO, Madam Therapeutics Jos Joore, CEO, MIMETAS B.V. Sijmen de Vries, President & CEO, Pharming Group NV Bernd van Buuren, CEO, Protinhi B.V. van de Sande, CEO, Synaffix B.V. Hans Preusting, CEO, Synerkine Pharma Erik van den Berg, CEO, AM-Pharma Rob Meijer, CEO, Amphera BV Aram Krol, CEO, Euretos Troels Jordansen, CEO, Glycostem Therapeutics B.V. Marco de Boer, CEO, NTrans Technologies BV Katrien Reynders, CEO, Pan Cancer T Han van 't Klooster, CEO, PHarmaCytics Willemijn Vader, CEO, VitroScan B.V.

Switzerland

Carlo Bertozzi, CEO, Acthera Therapeutic Werner Tschollar, CEO, AMYRA Biotech AG Marc Gitzinger, CEO, BioVersys AG Michael Bauer, CEO, Cellestia Lorenzo Bosisio, CEO, EffRx Pharmaceuticals Anne Schmidt, CEO, Elthera AG Filippo Riva, Managing Director, Humabs BioMed SA Jean-Paul Clozel, CEO, Idorsia Alcide Barberis, CEO, Mabylon AG Miro Venturi, CEO, Sintetica Klaas Zuideveld, CEO, Versameb

Germany

Sebastian Guth, Head of the Americas, Bayer Jean-Michel Boers, President & CEO, USA, Boehringer Ingelheim Antje Roetger, CEO, Carpegen GmbH Johannes Bacher, Managing Director, Co-Founder, Curetis GmbH Klaus Afflerbach, CEO, Navigo Proteins

Australia

Geoff Daly, CEO, Analytica Ltd Paul Perreault, Managing Director & CEO, CSL Behring

Canada

Russell Mcallister, CEO, Bold Therapeutics Inc. Sanj Singh, CEO, Temple Therapeutics

Denmark

Preben Bruun-Nyzell, CEO, 2N Pharma Lars Fruergaard Jørgensen, CEO, Novo Nordisk

France

David Loew, CEO, Ipsen Pharma SAS Paul Hudson, CEO, Sanofi

Italy

Alessandro Sidoli, CEO, Axxam SpA Lucio Rovati, CEO & Chief Scientific Officer, Rottapharm Biotech

Japan

Osamu Okuda, CEO & President, Chugai Pharmaceutical Co., Ltd. Christophe Weber, CEO, Takeda Pharmaceuticals

Lithuania

Arnas Karuzas, CEO, Ligence Rimantas Tuskevicius, CEO, SatiMed

Ireland

Timothy P. Walbert, President & CEO, Horizon Therapeutics Bruce Cozadd, Chairman & CEO, Jazz Pharmaceuticals

Israel

Oren Glanz, CEO, Lempo Therapeutics

Portugal

Simão Soares, CEO & Co-Founder, SilicoLife

Spain

Luis Mora Capitan, Managing Director, Pharma Mar

Supporting Biotechnology Associations

Michelle McMurry-Heath, President & CEO, BIO Steve Bates, Chair, International Council of Biotechnology Associations and CEO, UK BioIndustry Association Lorraine Chiroiu, CEO, AusBiotech Andrew Casey, President & CEO, BIOTECanada Patricia Trinler, President, CR biomed Claire Skentelbery, Director General, EuropaBio Franck Mouthon, Chairman, France Biotech Viola Bronsema, CEO, Secretary General, Bio Deutschland Ricardo Gent, Executive Director, German Association of Biotechnology Industries Matt Moran, Director, BioPharmaChem Ireland Riccardo Palmisano, President, Federchimica Assobiotec Osamu Nagayama, President, Japan Bioindustry Association Annemiek Verkamman, Managing Director, HollandBIO Simão Soares, CEO & President, P-BIO Ion Arocena, CEO, AseBio (Spanish Bioindustry Association) Helena Strigård, Director General, SwedenBIO Michael Altorfer, CEO, Swiss Biotech Association Wallace Lin, President, Taiwan Bio Industry Organization Rachel Lane, Executive Director, BIO Alabama Joan Koerber-Walker, President & CEO, Arizona Bioindustry Association, Inc. (AZBio) Joe Panetta, President & CEO, Biocom California Mike Guerra, President & CEO, California Life Sciences Ahmed Enany, President, Southern California Biomedical Council (SoCalBio) Jennifer Paton, President & CEO, Colorado BioScience Association Michael Fleming, President, Delaware BioScience Association Maria Thacker-Goethe, President & CEO, Georgia Bio Jessica Hyland, Executive Director, Iowa Biotechnology Association John Conrad, President & CEO, Illinois Biotechnology Innovation Organization Kristin Jones, President & CEO, Indiana Health Industry Forum Kendalle Burlin O'Connell, President & COO, MassBio Stephen Rapundalo, President & CEO, Michigan Biosciences Industry Association (MichBio) Kelly Gillespie, President & CEO, Missouri Biotechnology Association Rob Owen, Executive Director, Bio Nebraska Debbie Hart, President & CEO, BioNJ Greg Byrnes, Executive Director, NMBio Jennifer Hawks Bland, CEO, NewYorkBIO Erin Ford, Interim President & CEO, South Carolina BIO (SCBIO) Abby Trotter, Executive Director, Life Science TN Tom Kowalski, President & CEO, Texas Healthcare and Bioscience Institute (THBI) Leslie Alexandre, President & CEO, Life Science Washington Laura Gunter, Interim CEO, NCBio Ivan Lugo, Executive Director, INDUNIV Research Center, Inc Robb Stoddard, President & CEO, BioAlberta Meaghan Seagrave, Executive Director, BioNB Jason Field, President & CEO, Life Sciences Ontario Rory Francis, CEO, Prince Edward Island BioAlliance

Endnotes

ⁱ Biotechnology Innovation Organization, **COVID -19 Biotracker**, <u>https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/pipeline-trackerink</u>

" Ibid.

ⁱⁱⁱ List of Global Vaccine Partnerships, <u>https://www.bio.org/sites/default/files/2021-</u> 05/Industry_Partnerships_on_COVID_BIO.pdf

^{iv} <u>https://global-health-summit.europa.eu/rome-declaration_en</u>

v <u>https://www.bio.org/sites/default/files/2021-05/Airfinity_production.pdf</u>